Joe Fredette is a senior business development manager with the Biopharmaceuticals team at Waters. He is focused on understanding the analytical needs and challenges of our biopharmaceutical customers, and on applying that knowledge toward the development and promotion of LC-MS solutions that improve performance, solve analytical challenges, and fuel greater productivity.
Solving analytical challenges is at the core of our DNA and when it comes to oligonucleotide analysis, we’re at a point now where we can bring together the many advancements we’ve made across the analytical value stream into complete end-to-end workflows that truly deliver best-in-class analytical performance and productivity.
Learn how the BioAccord LC-MS System is instrumental in the drug development workflow from sample prep to reporting.
Oligonucleotides, or short strands of DNA or RNA, continue to increase in popularity. In addition to their essential role as primers and probes in the expanding clinical DNA testing and diagnostics market, they’re also seeing great success as new gene-based therapeutics that hold tremendous promise. With a string of recent drug approvals, including the first…
In January of 2018, Waters kicked off its global Bioharmonization campaign with a blog post and video release, laying out a vision for how the Biopharmaceutical industry can achieve accelerated development and improved quality while enhancing productivity and lowering production costs. Central to this vision are “fit-for-purpose” analytical tools working together within a single compliance-ready…
Analytical data can be so much more than a historical point in time documented in a single report. In fact, biopharmaceutical organizations can use LC-MS data to build a continuum of compliance.
For biopharmaceutical organizations working with contract labs, it’s important to consider how data and methods will be transferred and how generated data will be managed so that it meets data integrity and compliance requirements.
Analytical methods transfer. Data integrity. A changing and more stringent regulatory landscape. All this, and more, impacts productivity in upstream and downstream biopharmaceutical processes. How is Waters looking to help address development challenges for biologics and biosimilars?
From oligonucleotides and peptides to messenger RNA and CRISPR, ’tides are enjoying their time in the sun A year ago we wrote how oligonucleotide therapeutic development, which had seen a huge wave of investment in the late 1990s and early 2000s followed by a precipitous decline in the late 2000s, was once again on the…
Oligonucleotide drug development has seen its share of ups and downs over the past 20 years – but why? The promise of antisense oligonucleotides (ASOs) and later small interfering oligonucleotides (siRNAs) as therapeutics that can “dial down” or even “turn off” the expression of specific genes/proteins (“gene silencing”) remains high, yet companies dedicated to their…